检索结果-南通市图书馆

changes in hepatic fibrosis and incidence of HCC following direct-acting antiviral treatment of F3 chronic hepatitis c patients:a prospective observational study

引用

Hepatoma Research 2022年第1期8卷 340-351页

作者： Gamal Shiha Reham Soliman Ayman AHassan Nabiel N.H.Mikhail Egyptian Liver Research Institute and Hospital(ELRIAH) SherbinMansoura 35111Egypt Hepatology and Gastroenterology Unit Internal Medicine DepartmentFaculty of MedicineMansoura UniversityMansoura 35516Egypt Tropical Medicine Department Faculty of MedicinePort Said UniversityPort Said 42526Egypt Biostatistics and Cancer Epidemiology Department South Egypt Cancer InstituteAssiut UniversityAssiut 71515Egypt

Aim:Studies of clinical outcomes in chronic hepatitis C(CHC)patients with pretreatment advanced liver fibrosis(F3)after sustained virologic response(SVR)are scarce,and most studies are of small cohorts and retrospective in *** aim was to assess the clinical outcomes following direct acting antiviral(DAA)treatment among hepatitis C F3 patients after ***:This study included 1517 chronic hepatitis C patients with F3 fibrosis receiving DAAs in the out-patient clinics at the Egyptian Liver Research Institute and Hospital(ELRIAH).We included patients 18 years or older with HCV who received DAAs,have F3 by transient elastography,and have no history of hepatocellular carcinoma(HCC).Patients were followed up every six months after end of treatment using ultrasonography and ***:Significant improvement of fibrosis occurred with decreases in LSM,FIB-4,APRI,and *** changes in LSM were categorized depending on delta LSM,873 patients(57.5%)showed regression,454(29.9%)were stable,and 190 patients(12.5%)showed progression of ***,33 cases developed HCC during follow-up with incidence rate of 0.915/100 py(95%CI:0.64-1.27).Incidence was high with progression of liver fibrosis(6.17/100 py)compared to patients with stable fibrosis(1.09/100 py)and regression of liver fibrosis(0.75/100 py).There were no significant differences as regards fibrosis indicators at baseline(LSM,FIB-4,APRI,and FIB-6)between those who developed HCC and those who did ***:CHC Patients with F3 fibrosis showed a high rate of regression of fibrosis and decreased HCC incidence after achieving SVR following DAAs.

关键词： HCC fibrosis changes F3 DAAs

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：